MX2021004875A - Polipeptido de peptido tipo glucagon (glp-1) que tiene actividad agonista de receptor del glp-1 y uso del mismo. - Google Patents

Polipeptido de peptido tipo glucagon (glp-1) que tiene actividad agonista de receptor del glp-1 y uso del mismo.

Info

Publication number
MX2021004875A
MX2021004875A MX2021004875A MX2021004875A MX2021004875A MX 2021004875 A MX2021004875 A MX 2021004875A MX 2021004875 A MX2021004875 A MX 2021004875A MX 2021004875 A MX2021004875 A MX 2021004875A MX 2021004875 A MX2021004875 A MX 2021004875A
Authority
MX
Mexico
Prior art keywords
glp
polypeptide
receptor agonist
agonist activity
proline
Prior art date
Application number
MX2021004875A
Other languages
English (en)
Inventor
Jianning Liu
Jingyi Wang
Original Assignee
Jianning Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jianning Liu filed Critical Jianning Liu
Publication of MX2021004875A publication Critical patent/MX2021004875A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente solicitud pertenece al campo de medicina. La presente solicitud se refiere a un polipéptido de GLP-1 que tiene actividad de agonista de receptor de GLP-1 y uso del mismo. La presente solicitud se refiere además a una composición farmacéutica que comprende el polipéptido de GLP-1. En particular, la presente solicitud se refiere a un polipéptido de GLP-1 que tiene actividad de agonista de receptor de GLP-1, o una sal farmacéuticamente aceptable de la misma, en donde el polipéptido de GLP-1 tiene una mutación de treonina a prolina en la posición que corresponde a la 13° posición de la secuencia de aminoácidos de GLP-1.
MX2021004875A 2018-10-30 2018-10-30 Polipeptido de peptido tipo glucagon (glp-1) que tiene actividad agonista de receptor del glp-1 y uso del mismo. MX2021004875A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/112789 WO2020087305A1 (zh) 2018-10-30 2018-10-30 具有glp-1受体激动剂活性的glp-1多肽及其用途

Publications (1)

Publication Number Publication Date
MX2021004875A true MX2021004875A (es) 2021-08-11

Family

ID=70463349

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004875A MX2021004875A (es) 2018-10-30 2018-10-30 Polipeptido de peptido tipo glucagon (glp-1) que tiene actividad agonista de receptor del glp-1 y uso del mismo.

Country Status (7)

Country Link
US (1) US11141464B2 (es)
EP (1) EP3875476A4 (es)
JP (1) JP7221385B2 (es)
KR (2) KR20210081376A (es)
BR (1) BR112021008180A2 (es)
MX (1) MX2021004875A (es)
WO (1) WO2020087305A1 (es)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6479101A (en) * 2000-06-16 2002-01-02 Lilly Co Eli Glucagon-like peptide-1 analogs
US20030199445A1 (en) * 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
JP5685355B2 (ja) * 2002-07-04 2015-03-18 ジーランド ファーマ アクティーゼルスカブ Ｇｌｐ−１および糖尿病の処置方法
CN1918177A (zh) * 2003-12-18 2007-02-21 诺和诺德公司 新型glp－1化合物
ES2541633T3 (es) * 2005-01-14 2015-07-22 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Exendinas modificadas y usos de las mismas
ATE550032T1 (de) * 2005-04-11 2012-04-15 Amylin Pharmaceuticals Inc Verwendung von glp-1, exendin und agonisten davon zur verzögerung oder verhinderung von kardialer remodellierung
CN105056211A (zh) * 2005-08-19 2015-11-18 安米林药品有限责任公司 治疗糖尿病和降低体重的毒蜥外泌肽
US8318668B2 (en) 2005-09-08 2012-11-27 Trustees Of Tufts College Stabilized GLP-1 analogs
EP1942115A4 (en) 2005-10-26 2009-03-18 Chugai Pharmaceutical Co Ltd AGGLUTINABLE GLP-1 ANALOGUE AND PROLONGED RELEASE PHARMACEUTICAL COMPOSITION
CN1786031B (zh) 2005-12-16 2011-05-25 暨南大学 胰高血糖素样多肽-1类似物及其制备方法与应用
CN101985470B (zh) * 2005-12-16 2012-02-22 暨南大学 胰高血糖素样多肽-1类似物及其制备方法与应用
US20100256056A1 (en) * 2007-09-07 2010-10-07 Zheng Xin Dong Analogues of exendin-4 and exendin-3
CN101337989B (zh) 2008-08-28 2012-10-24 中国药科大学 一类新型胰高血糖素样肽-1(glp-1)类似物及其应用
CN101891823B (zh) * 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
CN102766204B (zh) * 2011-05-05 2014-10-15 天津药物研究院 胰高血糖素样肽-1突变体多肽及其制备方法和其应用
CN104262481B (zh) 2013-08-09 2018-02-09 天津药物研究院有限公司 一种侧链修饰的长效glp‑1类似物的制备方法及其应用
CN108271356A (zh) * 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
US10493125B2 (en) * 2015-12-09 2019-12-03 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and GLP-1 receptors
CN116396375A (zh) * 2017-07-21 2023-07-07 苏州瑞德升跃制药技术有限公司 具有glp-1受体激动剂活性的glp-1多肽及其用途

Also Published As

Publication number Publication date
KR20210081376A (ko) 2021-07-01
JP2022512908A (ja) 2022-02-07
EP3875476A4 (en) 2022-08-24
WO2020087305A1 (zh) 2020-05-07
BR112021008180A2 (pt) 2021-08-03
EP3875476A1 (en) 2021-09-08
JP7221385B2 (ja) 2023-02-13
US20200215161A1 (en) 2020-07-09
US11141464B2 (en) 2021-10-12
KR20240044545A (ko) 2024-04-04

Similar Documents

Publication Publication Date Title
MX2021015328A (es) Agonistas del receptor del peptido-1 similar al glucagon.
PH12020551066A1 (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2018067217A3 (en) COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
PE20220938A1 (es) Compuestos agonistas de gipr
NZ603445A (en) Gip-based mixed agonists for treatment of metabolic disorders and obesity
AR093903A1 (es) Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
MY202069A (en) Pharmaceutical composition
BR112018000903A2 (pt) composições e métodos para o tratamento de câncer
EP3939606A3 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
NO20093064L (no) Templatfikserte peptidhermere
NZ608502A (en) Polypeptides that bind to human complement component c5
WO2019215063A8 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
MX2019006600A (es) Agonistas duales de glp-1/glp-2.
PH12019550241A1 (en) Mic-1 compounds and uses thereof
EA202190650A1 (ru) Замедленная доставка ангиопоэтин-подобных полипептидов 3
MX347229B (es) Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.
MX2022014368A (es) Compuesto de agonista doble para receptores de glp-1 y gip y aplicacion del mismo.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
MX2023008330A (es) Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
MX2021004875A (es) Polipeptido de peptido tipo glucagon (glp-1) que tiene actividad agonista de receptor del glp-1 y uso del mismo.
NZ592670A (en) Corticotrophin releasing hormone receptor 2 peptide agonists and uses thereof